A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
NCT01986933
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
264
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
nemolizumab (CIM331)
OTHER:
Placebo
Sponsor
Chugai Pharmaceutical